The tumor-regressive effect of JZL184 was accompanied by a dose-dependent reduction in the angiogenesis marker CD31 (Figure 7B) and a likewise dose-dependent increase in TIMP-1-positive cells in xenografts. This evidence concerns the gene TIMP1 and neoplasm.